润达医疗(603108) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company forecasts a net loss for H1 2025, with attributable net profit expected to range from -RMB 130 million to -RMB 109 million Estimated Financial Performance for H1 2025 | Indicator | Estimated Amount (RMB Million) | | :--- | :--- | | Net Profit Attributable to Parent Company | -130.37 to -108.64 | | Net Profit Attributable to Parent Company (Excluding Non-Recurring Items) | -144.94 to -120.78 | - The financial data in this performance forecast has not been audited by a certified public accountant[6] Prior Period Performance Review The company achieved profitability in the prior year's corresponding period, with net profit attributable to shareholders of RMB 91.31 million Prior Period Financial Performance (H1 2024) | Indicator (H1 2024) | Amount (RMB Million) | | :--- | :--- | | Net Profit Attributable to Parent Company | 91.31 | | Net Profit Attributable to Parent Company (Excluding Non-Recurring Items) | 79.19 | | Earnings Per Share (RMB) | 0.15 | Analysis of Pre-Loss Performance The current period's loss is primarily due to centralized procurement policies impacting the in-vitro diagnostics industry, leading to reduced revenue and gross profit margins - The core negative impact stems from centralized procurement policies in the in-vitro diagnostics industry, leading to a year-on-year decline in the company's revenue and gross profit margin[9] - Fixed expenses such as employee compensation, accumulated depreciation and amortization, and financing costs did not decrease proportionally with revenue, exacerbating the loss[9] - The company actively implemented cost-reduction and efficiency-improvement measures, resulting in a year-on-year increase of over 50% in net cash flow from operating activities during the reporting period[9] Risk Warning and Other Disclosures This performance forecast is a preliminary, unaudited estimate; final data will be in the 2025 semi-annual report, cautioning investors of risks - The data in this performance forecast is a preliminary estimate and unaudited, thus subject to uncertainty[10] - The specific and accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report; investors are advised to be aware of investment risks[11]